Abstract
Out of 19 patients with extrinsic bronchial asthma challenged with 123 μg histamine acid phosphate by intravenous infusion only 13 responded with a fall in FEV1 of over 10% (mean 16%). Seventeen of these patients were given histamine 2 mg/ml by aerosol, and all responded with a mean decrease in FEVi of 37.8%. When challenged with allergen extract by aerosol the mean decrease in FEVi was 37.5%. After 40 mg sodium cromoglycate 15 of the 17 patients showed significant protection against allergen challenge with a mean decrease in FEV1 of only 23.6%. Inhalation of 40 mg sodium cromoglycate, however, failed to protect against histamine given by either the intravenous or aerosol route. Histamine given intravenously to asthmatic patients produces less of a bronchial response than when given by aerosol, even though the intravenous route produces many more systemic symptoms, such as flushing and throbbing headache. The protection of sodium cromoglycate against an allergen inhalation challenge is not due to histamine antagonism.
| Original language | English |
|---|---|
| Pages (from-to) | 867-870 |
| Number of pages | 4 |
| Journal | British Medical Journal |
| Volume | 1 |
| Issue number | 6014 |
| DOIs | |
| State | Published - Apr 10 1976 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
Bronchial reactivity to histamine before and after sodium cromoglycate in bronchial asthma. / Kang, Bann; Lee, C. K.; Kolotkin, Betty Miller; Townley, Robert G.
In: British Medical Journal, Vol. 1, No. 6014, 10.04.1976, p. 867-870.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Bronchial reactivity to histamine before and after sodium cromoglycate in bronchial asthma
AU - Kang, Bann
AU - Lee, C. K.
AU - Kolotkin, Betty Miller
AU - Townley, Robert G.
PY - 1976/4/10
Y1 - 1976/4/10
N2 - Out of 19 patients with extrinsic bronchial asthma challenged with 123 μg histamine acid phosphate by intravenous infusion only 13 responded with a fall in FEV1 of over 10% (mean 16%). Seventeen of these patients were given histamine 2 mg/ml by aerosol, and all responded with a mean decrease in FEVi of 37.8%. When challenged with allergen extract by aerosol the mean decrease in FEVi was 37.5%. After 40 mg sodium cromoglycate 15 of the 17 patients showed significant protection against allergen challenge with a mean decrease in FEV1 of only 23.6%. Inhalation of 40 mg sodium cromoglycate, however, failed to protect against histamine given by either the intravenous or aerosol route. Histamine given intravenously to asthmatic patients produces less of a bronchial response than when given by aerosol, even though the intravenous route produces many more systemic symptoms, such as flushing and throbbing headache. The protection of sodium cromoglycate against an allergen inhalation challenge is not due to histamine antagonism.
AB - Out of 19 patients with extrinsic bronchial asthma challenged with 123 μg histamine acid phosphate by intravenous infusion only 13 responded with a fall in FEV1 of over 10% (mean 16%). Seventeen of these patients were given histamine 2 mg/ml by aerosol, and all responded with a mean decrease in FEVi of 37.8%. When challenged with allergen extract by aerosol the mean decrease in FEVi was 37.5%. After 40 mg sodium cromoglycate 15 of the 17 patients showed significant protection against allergen challenge with a mean decrease in FEV1 of only 23.6%. Inhalation of 40 mg sodium cromoglycate, however, failed to protect against histamine given by either the intravenous or aerosol route. Histamine given intravenously to asthmatic patients produces less of a bronchial response than when given by aerosol, even though the intravenous route produces many more systemic symptoms, such as flushing and throbbing headache. The protection of sodium cromoglycate against an allergen inhalation challenge is not due to histamine antagonism.
UR - http://www.scopus.com/inward/record.url?scp=0017255099&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017255099&partnerID=8YFLogxK
U2 - 10.1136/bmj.1.6014.867
DO - 10.1136/bmj.1.6014.867
M3 - Article
VL - 1
SP - 867
EP - 870
JO - The BMJ
JF - The BMJ
SN - 0959-8146
IS - 6014
ER -